Description
Sermorelin is the 1-29 fragment of human growth-hormone-releasing hormone — the shortest fully active GHRH sequence. Originally developed as a diagnostic agent, it is studied in somatotropic-axis research as the reference GHRH analogue.
10 vials per box. Strengths are per vial; prices are per box.
Research summaries
GHRH(1-29) as the minimal active fragment
Structure-activity research established that the first 29 residues of GHRH retain full receptor activity, making sermorelin the benchmark for GHRH-analogue design and pituitary-function testing.
Sermorelin is the original template against which newer GHRH analogues are compared.
Diagnostic and secretagogue research history
Sermorelin’s development as a GH-deficiency diagnostic produced a substantial human pharmacology record, including dose-response and pulsatility data that still anchor secretagogue study design.
Because sermorelin was developed as an approved diagnostic, it has more human data than most research peptides.
For research use only. Not for human or veterinary use.
